The role of p-Stat3 Y705 immunohistochemistry in glioblastoma prognosis

Sergiu Susman1,2*, Radu Pîrlog1, Daniel Leucuța3, Andrei Otto Mitre4, Vlad Adrian Padurean5, Carmen Melincovici1, Ioana Moldovan1, Doina Crișan1,6 and Stefan Ioan Florian4,5

Abstract

Background: In spite of the multimodal treatment used today, glioblastoma is still the most aggressive and lethal cerebral tumour. To increase survival in these patients, novel therapeutic targets must be discovered. Signal transducer and activator of transcription 3 (Stat3), a transcription factor that controls normal cell differentiation and survival is also involved in neoplastic cell transformation. In this study we evaluated the immunohistochemical expression of pY705-Stat3 in patients with primary glioblastoma and determined its prognostic role by correlating it with survival.

Methods: This retrospective study included 94 patients diagnosed with glioblastoma. We determined the localization, number of positive cells, and marker intensity for pY705-Stat3 in these patients with the use of immunohistochemistry. The prognostic role was determined by correlating pY705-Stat3 expression on formalin-fixed paraffin-embedded tumour tissues with the patient’s survival in univariate and multivariate COX regressions.

Results: We found a statistically significant difference in survival between the patients with more than 20% pY705-Stat3 positive cells and those with less than 20% pY705-Stat3 positive cells (8.9 months median survival versus 13.7 months median survival, \( p < 0.001 \)). On multivariate analyses with the COX proportional hazards regression model including pY705-Stat3 expression, age and relapse status, pY705-Stat3 status was an independent prognostic factor in glioblastoma (\( p < 0.001 \)).

Conclusion: The results obtained show that the immunohistochemical expression of pY705-Stat3 correlates with survival in glioblastoma. This study identifies Stat3 as a possible target for existing or new developed Stat3 inhibitors.

Keywords: Glioblastoma, Stat3, Immunohistochemistry, Prognosis

Background

According to the 2016 WHO classification, glioblastoma is classified as a grade IV, being known to be one of the most lethal brain tumours [1]. Standard treatment includes surgical resection followed by adjuvant radiotherapy and chemotherapy [2]. Despite the multimodal treatment used at present, median survival remains very low, and new therapies are required to increase survival in these patients [3].

From a histopathological point of view, glioblastoma is characterized by necrosis and microvascular proliferation, elements that reflect an intra-tumour heterogeneity in terms of cell adaption to hypoxia [1].

Adaptation to hypoxia leads to the specific activation of the genetic programs and signalling pathways that are also involved in the stem-like phenotype or epithelial-mesenchymal (EMT) transition, with the subsequent increase in resistance to chemotherapy and radiotherapy [4–6]. Recent studies that have attempted to decode the molecular mechanisms involved in hypoxic cell

* Correspondence: serman_s@yahoo.com
1Department of Morphological Sciences, Iuliu Hațieganu University of Medicine and Pharmacy, 6 Pasteur Street, 400349 Cluj-Napoca, Romania
2Department of Pathology, Imogen Research Centre, Cluj-Napoca, Romania
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
adaptation in glioblastoma have shown that the major signalling pathways activated in hypoxia are those of the hypoxic inducible factor 1α (HIF-1α) vascular endothelial growth factor (VEGF), transforming growth factor beta (TGFβ), mammalian target of rapamycin (mTOR), CD133, as well as of signal transducer and activator of transcription 3 (Stat3) [6–9].

Stat3 protein is a regulator of cell survival, proliferation, differentiation and apoptosis; it also regulates cell adaptation to hypoxia by stimulating angiogenesis in several types of cancers [6–11]. As a transcription factor, Stat3 is activated by phosphorylation; after dimerization it translocates into the nucleus, where it binds to the DNA, activating specific cellular pathways [12].

Elevated levels of Stat3 have been highlighted in various types of cancer, including thyroid cancer, melanoma, prostate cancer, Hodgkin’s lymphoma, breast cancer, hepatocellular carcinoma and glioblastoma [11, 13]. Being involved in numerous signalling pathways and over-expressed in tumour cells compared to normal tissues, Stat3 is considered to be a potential target for future antitumor therapies [10, 12].

In vitro studies have demonstrated the role of Stat3 in glial tumour biology, especially in glioblastoma, being directly involved in maintaining the stem-like phenotype, EMT (epithelial-mesenchymal transition), resistance to alkylating agents such as temozolomide (TMZ) and radiotherapy [5, 14, 15]. Furthermore, in vitro inhibition of Stat3 activation in glioblastoma resulted in a decrease in the proliferative capacity and an increase in cellular sensitivity to TMZ treatment [10, 15, 16]. Although there is a wide range of in vitro studies showing the importance of Stat3 in glioblastoma, there are only a few clinically oriented studies that correlate Stat3 expression with patient survival [17–19].

In this study, we evaluated the prognostic role of the immunohistochemical expression of p-Stat3Y705 in a series of primary glioblastoma patients. In addition, we attempted to establish a threshold for the immunohistochemical expression of this marker that has prognostic significance.

Methods

Patients

This retrospective study included 94 patients diagnosed with glioblastoma. Formalin-fixed paraffin-embedded tissue samples were obtained from the archive of the Emergency County Hospital Pathology Department in Cluj-Napoca, Romania. The patients were operated in the period 2009–2015 in the Neurosurgery Department of the same institution. All patients underwent the standard postoperative treatment (chemotherapy and radiotherapy). Patients were regularly checked according to standard protocols. The overall survival time was measured from the time of the first diagnosis of glioblastoma until death.

The diagnosis of glioblastoma was confirmed by two experienced pathologists (SS and DC) in line with the current WHO classification system [1]. We examined the medical record of each patient to determine age, gender, tumour volume (calculated by the product of the three diameters of the tumor divided by 2 [20]), tumour localization, relapse and survival.

The study was conducted with the approval of the Ethics Committee of the Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca, Romania.

Immunohistochemistry

Immunohistochemistry was performed automatically on 3-μm-thick sections of formalin-fixed and paraffin-embedded tumour specimens with DAKO Omnis®, using the ethylenediaminetetraacetic acid (EDTA), at pH = 9, for antigen retrieval. For the immunohistochemical assessment of Stat3 expression, the specimens were incubated overnight at 4°C with Phospho-Stat3 (Tyr705) antibody, clone D3A7 (Cell Signalling Technology, Inc., Danvers, MA) at a 1:400 dilution. Positive and negative controls were used in line with the recommendation of the manufacturer. We assessed the percentage of Stat3 positive tumour cells (0–100%) and immunostaining intensity (absent, poor, moderate or intense). For all cases the area of necrosis was assessed by morphometry, using an Olympus BX 46 microscope. Images were taken with an Olympus UC 30 camera system with UI52 with an infinity correction optical system and processed in the LabSense 1.2 Olympus Software by GmbH Imaging Solutions.

The slides were read independently by two experienced pathologists with no knowledge of clinical data. In the case of divergent results, the slides were reviewed by both pathologists working together, and consensus was reached. The K score for the two pathologists that analysed the specimens was 0.81.

Statistical analysis

Categorical data were presented as absolute and relative frequencies. Continuous data that did not follow the normal distribution were presented as the median and interquartile range (IQR). Overall survival (OS) was defined as the period from the primary surgery until death of the patient. We considered a 20% positivity of tumour cells as a cut-off for STAT3 immunopositivity, which respected the proportional hazard assumption for the Cox regression. The cut-off point was initially set to >0, >5%, and then increased to 10%, and then 20%. We increased the cut-off points because the proportional hazard assumption was not met for >0, 5, 10%, but it was met for 20%. Comparisons between groups in respect of survival were performed using the long-rank test, and
presented with a Kaplan Meier plot. The STAT3 immunopositivity was assessed univariately and then in a multivariate model (adjusting for age and tumour localization) using Cox proportional hazards regression analysis. We checked the proportional hazard assumption with a formal test. Results were expressed as a hazard ratio and its corresponding 95% confidence interval. A two tailed \( p \)-value less than 0.05 was considered as statistically significant. All analyses were performed in R environment for statistical computing and graphics, version 3.2.3.

**Results**

Table 1 presents the characteristics of the patients included in our study by age, gender, tumour volume, location and clinical evolution (death and relapse).

Regarding localization, the tumours were mainly located in the frontal, parietal, temporal and occipital lobes. Other locations included: brainstem, cerebellum, pineal zone, basal ganglia, corpus callosum. All patients received multimodal treatment (surgery followed by radiotherapy and chemotherapy). Data regarding the actual treatment received were available for 53 patients (44 received both radiotherapy and chemotherapy, and three received radiotherapy). The doses were 75 mg/m\(^2\) for TMZ, and 60 Gy in 15 fractions for the radiotherapy.

**Stat3 immunohistochemistry**

We found p-Stat3 Y705 immunopositive cells in 89% of our glioblastoma cases. The percentage of p-Stat3 Y705 positive cells was low, with less than 5% positive cells in 18 (19.78%) cases, intermediate, with positive cells between 5 and 9% in 23 (25.27%) cases, and high, with more than 10% Stat3 positive cells in 50 (54.95%) cases. The intensity of the nuclear staining was absent in 10 (11%), poor in 43 (47.3%), moderate in 36 (39.6%) and intense in 2 (2.2%) of the cases. To assess the immunohistochemical marker, the entire tumour surface was analysed. This has the advantage of highlighting the number of positive cells, the intensity of the marker, and the distribution of positive cells across the entire tumour surface. In our series, we could observe heterogeneity, the cells being positive for p-Stat3 Y705 at the nuclear level mainly in the perinecrotic areas and at the tumour invasion front (Figs. 1 and 2).

p-Stat3 Y705 immunohistochemical expression influences survival in glioblastoma. We found a statistically significant survival difference between subjects with more than 20% p-Stat3 Y705 positive cells (17 months median follow-up), who had better survival rates than those with less than 20% positive cells (8 months median follow-up), \( p < 0.001 \), log-rank test (Fig. 3).

The same observation holds true in the Cox proportional hazards regression (HR) model in univariate and then in multivariate analyses, including p-Stat3 Y705 expression status (>20%) even after adjusting for age and different tumour localization (Table 2). Age remains an important survival predictor. Localization was not associated with survival, and only parietal localization was close to the statistically significant level as a predictor factor. Furthermore, we created other models to adjust for other prognostic factors besides p-Stat3 expression (Table 3). Thus, we added gender, tumour volume, and necrosis, and p-Stat3 Y705 expression status was an independent prognostic factor in glioblastoma (\( P < 0.001 \)). None of the adjusted factors was statistically significant associated with survival, except age and parietal localization.

**Table 1** Patient characteristics

| Characteristic          | N (%) (Total = 94)          |
|-------------------------|-----------------------------|
| Age (yr.) median (IQR)  | 51.5 (44–56)                |
| Gender                  |                             |
| M                       | 53 (56.4)                   |
| F                       | 41 (43.6)                   |
| Deceased                | 88 (93.62)                  |
| Relapse                 | 24 (25.5)                   |
| Tumor volume (cm\(^3\)) median (IQR) | 23.26 (10.35–44.81) |
| Localization            |                             |
| Left                    | 37 (39.4)                   |
| Right                   | 38 (40.4)                   |
| Bilateral               | 6 (6.4)                     |
| n.a.                    | 13 (13.8)                   |
| Frontal                 | 45 (47.87)                  |
| Parietal                | 22 (23.4)                   |
| Temporal                | 28 (29.79)                  |
| Occipital               | 12 (12.77)                  |
| Brainstem               | 2 (2.13)                    |
| Other                   | 11 (11.7)                   |

**Discussion**

In this study, we evaluated the p-Stat3y705 expression in a group of primary glioblastomas by immunohistochemistry and correlated the expression with the overall survival. In our study, an increased number of immunopositive p-Stat3y705 cells correlated with a reduced overall survival. Our data are in line with those of previous studies reporting that an increase of Stat3 level associates with a poor prognosis in glioblastoma patients, highlighting the clinical value of Stat3 evaluation for patients with glioblastoma [17–19]. These results support the importance of a routine immunohistochemical evaluation of the phosphorylation status of p-Stat3y705 as a prognostic marker of clinical interest for patients with glioblastoma regardless of age or relapse status.
It is important to note that by evaluating the whole tumour surface, we observed a specific localization for Stat3 immunopositivity in cells that surround the necrotic areas, but also in cells located at the tumour invasion front. This suggests the presence of an intratumoural heterogeneity of cells in terms of the activated intracellular signalling pathways and could account for the resistance of a subset of cells to the current treatment, and the high relapse rate.

The perinecrotic localization of p-Stat3Y705 immunopositive cells suggests the activation of the signalling pathways involved in cellular adaptation to hypoxia, Stat3 being a potent activator of HIF-1α, and VEGF [19, 21]. HIF-1 can also be activated by mTOR proteins, either directly or via the STAT3 pathway [22, 23]. HIF-1 is known to be involved in stimulating tumour motility and radio resistance to current therapies, explained by the formation of “palisades” due to an outward migration of tumour cells toward the more vascularised zones [19, 24, 25]. VEGF can be up-regulated either by Stat3 and/or by HIF-1. Through its expression, it promotes the activation of neoangiogenesis in glioblastoma, highlighting the role of Stat3 in cellular adaptation in extreme conditions [7, 21, 26]. Furthermore, Stat3 is an activator of the epithelial-mesenchymal transition (EMT) process in glioblastoma, both through TGFβ and HIF-1α, thus enhancing tumour high motility, invasiveness and chemo resistance, which could account for the positivity of cells at the invasion front [27–30]. HIF-1 and Stat3 can also activate the transcription of zinc finger transcription factor (ZEB) proteins, especially ZEB1, which promotes EMT, migration and invasion [31, 32]. Stat3 activation in the invasion front cells could be an important observation. After surgical resection, these cells dispersed in the normal brain are at the origin of tumour recurrence. Developing inhibitors that target the signalling pathways activated specifically in cells at the tumour invasion front could lead to a more effective postoperative therapy.

Glioma stem cells (GSC) are a subtype of cells found in glioblastoma that are involved in tumour recurrence, initiation and invasiveness [33]. GSC are also believed to be involved in tumour chemo- and radio resistance to therapy [34]. CD133, a surface protein, is a known marker for GSC, its expression being correlated with tumour malignancy [23]. In low oxygenated cells, HIF-1α, mTOR, TGFβ and Stat3 levels were shown to increase CD133 expression in tumour cells, promoting
GSC formation and proliferation [6, 9, 14, 35, 36]. Altogether, hypoxia and Stat3 are involved in promoting glioblastoma stem-like cells, thus increasing tumour resistance and invasiveness [37–39].

O6-methylguanyl DNA methyltransferase (MGMT) is an enzyme that helps repair the damaged DNA sequence in glioblastoma, preventing alkylating chemotherapeutic agents such as TMZ to be fully efficient [40]. Epigenetic hypermethylation of the MGMT promoter silences the gene predicting a favourable response to alkylating chemotherapy in glioblastoma patients [41, 42]. Therefore, MGMT promoter methylation status can be used as a marker for resistance to treatment with alkylating agents, especially in elderly patients, where chemotherapy in unmethylated tumours evidenced minimal benefit [40, 43]. Stat3 expression is required for MGMT activity, and inhibition of Stat3 leads to a downregulation of MGMT, favouring TMZ therapy [16].

Regarding the in vitro studies that have evaluated Stat3 inhibition in GMB, Han et al showed that Cpd188 is able to enhance the effect of chemo-radiotherapy treatment.

![Cumulative overall survival of 94 patients with glioblastoma comparing subjects with less than 20% p-Stat3Y705 positive cells and those with more than 20% positive cells](image)

**Table 2** Univariate and multivariate Cox proportional hazard regression models predicting overall survival

|                  | Univariable |          |          |          |          |          |          |          |          |
|------------------|-------------|----------|----------|----------|----------|----------|----------|----------|----------|
|                  | HR          | (95% CI) | p-value  | HR       | (95% CI) | p-value  | HR       | (95% CI) | p-value  |
| Age (years)      | 1.02        | (1–1.05) | 0.039    | 1.04     | (1.01–1.06)| 0.01     |
| p-Stat3 percentage ≥ 20% | 4.86       | (2.91–8.11) | < 0.001 | 5.69     | (3.27–9.91)| < 0.001 |          |          |          |
| Frontal          | 0.84        | (0.55–1.28) | 0.419   | 1.02     | (0.61–1.71)| 0.945   |
| Parietal         | 0.86        | (0.52–1.41) | 0.555   | 0.6      | (0.35–1.04)| 0.068   |
| Temporal         | 0.94        | (0.59–1.49) | 0.799   | 0.84     | (0.5–1.42)| 0.522   |
| Occipital        | 0.81        | (0.44–1.5)  | 0.511   | 0.81     | (0.4–1.64)| 0.562   |
| Brainstem        | 1.24        | (0.3–5.07) | 0.764   | 2.91     | (0.62–13.75)| 0.177   |

The multivariate model includes all the variables in the table

A second model was created adding to these variables, gender, as well as tumour volume (cm³), where we found HR p-Stat3 percentage ≥ 20% = 4.86 (95% CI 2.91–8.11), p < 0.001

HR Hazard ratio, CI Confidence interval
for the cell lines with a p-Stat overexpression [44]. Another study has provided data regarding molecular mechanisms underlying hypoxia-induced glioma cell autophagy, evidencing that the inhibition of IL6-Stat3 axis represses autophagy in glioblastoma cell lines in vitro [45]. The same study has demonstrated a certain level of efficiency by blocking Il6 receptor with tocilizumab. Given that Stat3 is situated at the interconnection of signalling pathways that controls the cellular processes involved in hypoxia, resistance to treatment, EMT, the signalling pathways that controls the cellular processes in EMT:

Stat3 inhibitors are currently an important issue, as early clinical data has shown promising results in EGFR mutation- positive non-small cell lung cancer. However, more research is required to understand the different mechanisms that lead to the activation of STAT3 in order to design robust Stat3-targeted therapies [15]. Another example of inhibitors targeting Stat3 at different levels and currently used in clinical trials are: STAT3 antisense oligonucleotide (advanced stage/metastatic hepatocellular carcinoma) or STAT3 SH2 domain binder (multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukaemia, chronic myeloid leukaemia) [47]. Overall, these data could open the perspective for future clinical trials using Stat3 inhibitors in glioblastoma.

As with any observational study, potential confounders that were not taken into account could influence the observed results. We used multivariate analysis and we adjusted for several variables, but we didn’t include the different treatment timing/dosages.

**Conclusion**

Our results show that Stat3 expression can be evaluated by immunohistochemistry and has an important prognostic role in glioblastoma. Therefore, clinical approaches should consider including a Stat3 inhibitor in the therapeutic protocol in order to improve tumour response to radiotherapy and chemotherapy. Furthermore, another observation of our study is the preferred localization of Stat3 positive cells at the nuclear level of tumour cells in the perinecrotic areas and at the tumour invasion front. This discovery could suggest the presence of heterogeneous cell populations that are involved in tumour development and treatment resistance. In order to better understand the malignant potential of glioblastomas, we should consider glioblastoma consists of distinct cell subpopulations. This approach could uncover molecular contexts of susceptibility that will accelerate the development of new therapies targeting cells that matter.

**Table 3** Multivariate Cox proportional hazard regression models predicting overall survival, for p-Stat3 percentage adjusting for different confounders

| Models | HR   | (95% CI)          | P-value |
|--------|------|-------------------|---------|
| Model 1 | 5.69 | (3.27–9.91)       | < 0.001 |
| Model 2 | 4.86 | CI 2.91–8.11      | < 0.001 |
| Model 3 | 7.8  | (2.88–21.11)      | < 0.001 |

Model 1 - multivariate Cox proportional hazard regression model including age (years), Stat3 percentage >= 20%, localizations (frontal, parietal, temporal, occipital, brainstem)

Model 2 - model 1 plus gender and tumour volume (cm³)

Model 3 - model 2 plus necrosis (μm²)

HR: Hazard ratio, CI: Confidence interval

**Abbreviations**

CI: Confidence interval; EDTA: Ethylenediaminetetraacetic acid; EMT: Epithelial-mesenchymal transition; GSC: Glioma stem cells; HE: Hematoxylin-Eozin; HIF-1α: Hypoxic inducible factor 1α; HR: Hazard regression; IQR: Interquartile range; MGMT: O6-methylguanylnyl DNA methyltransferase; mTOR: Mammalian target of rapamycin; OS: Overall survival; Stat3: Signal transducer and activator of transcription 3; TGFβ: Transforming growth factor beta; TMZ: Temozolomide; VEGF: Vascular endothelial growth factor; yr.: Years; ZEB: Zinc finger transcription factor

**Acknowledgements**

Not applicable.

**Authors’ contributions**
SS designed the study, did the histological and immunohistochemical analysis of the samples, participated in writing the manuscript; RP collected the clinical data and took the histological samples from the archives, participated in writing the manuscript; DL did the statistical analysis; CM did the imaging diagnosis and follow-up of the tumours; IM and SIF performed the surgical intervention and clinical follow-up; VAP and AOM searched the archives and collected data about the patients and tumours; AOM participated in writing and editing the manuscript. All authors read and approved the final manuscript.

**Funding**
The study was supported by an internal grant (code 4944/4/08.03/2016) from the Iuliu Hațeganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

**Availability of data and materials**
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

The study was conducted with the approval of the Ethics Committee of Iuliu Hațeganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1Department of Morphological Sciences, Iuliu Hațeganu University of Medicine and Pharmacy, 6 Pasteur Street, 400349 Cluj-Napoca, Romania. 2Department of Pathology, Imogen Research Centre, Cluj-Napoca, Romania. 3Department of Medical Informatics and Biostatistics, Iuliu Hațeganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. 4Department of Neurosurgery, Iuliu Hațeganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. 5Department of Neurosurgery, Emergency County Hospital, Cluj-Napoca, Romania. 6Department of Pathology, Emergency County Hospital, Cluj-Napoca, Romania.
References

1. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20. https://doi.org/10.1007/s00401-016-1545-1.

2. Wilke-Olson E, Bolognese CM, Deligio A, Viscomi C, Khaibullin R, Kallós G, Hidalgo M, et al. Hypoxia and epithelial-to-mesenchymal transition in human glioblastoma. Acta Neuropathol. 2010;120:489–503. https://doi.org/10.1007/s00401-010-0756-0.

3. Kallós G, Hidalgo M, Viscomi C, Deligio A, Khaibullin R, Wilke-Olson E, et al. Epithelial-to-mesenchymal transition is associated with increased hypoxia-related angiogenesis and correlates with poor survival in glioblastoma. J Neuro-Oncol. 2011;102:249–57. https://doi.org/10.1007/s11060-011-0802-9.

4. Kallós G, Hidalgo M, Viscomi C, Deligio A, Khaibullin R, Wilke-Olson E, et al. Epithelial-to-mesenchymal transition is associated with increased hypoxia-related angiogenesis and correlates with poor survival in glioblastoma. J Neuro-Oncol. 2011;102:249–57. https://doi.org/10.1007/s11060-011-0802-9.

5. Kallós G, Hidalgo M, Viscomi C, Deligio A, Khaibullin R, Wilke-Olson E, et al. Epithelial-to-mesenchymal transition is associated with increased hypoxia-related angiogenesis and correlates with poor survival in glioblastoma. J Neuro-Oncol. 2011;102:249–57. https://doi.org/10.1007/s11060-011-0802-9.

6. Kallós G, Hidalgo M, Viscomi C, Deligio A, Khaibullin R, Wilke-Olson E, et al. Epithelial-to-mesenchymal transition is associated with increased hypoxia-related angiogenesis and correlates with poor survival in glioblastoma. J Neuro-Oncol. 2011;102:249–57. https://doi.org/10.1007/s11060-011-0802-9.

7. Kallós G, Hidalgo M, Viscomi C, Deligio A, Khaibullin R, Wilke-Olson E, et al. Epithelial-to-mesenchymal transition is associated with increased hypoxia-related angiogenesis and correlates with poor survival in glioblastoma. J Neuro-Oncol. 2011;102:249–57. https://doi.org/10.1007/s11060-011-0802-9.

8. Kallós G, Hidalgo M, Viscomi C, Deligio A, Khaibullin R, Wilke-Olson E, et al. Epithelial-to-mesenchymal transition is associated with increased hypoxia-related angiogenesis and correlates with poor survival in glioblastoma. J Neuro-Oncol. 2011;102:249–57. https://doi.org/10.1007/s11060-011-0802-9.

9. Kallós G, Hidalgo M, Viscomi C, Deligio A, Khaibullin R, Wilke-Olson E, et al. Epithelial-to-mesenchymal transition is associated with increased hypoxia-related angiogenesis and correlates with poor survival in glioblastoma. J Neuro-Oncol. 2011;102:249–57. https://doi.org/10.1007/s11060-011-0802-9.

10. Kallós G, Hidalgo M, Viscomi C, Deligio A, Khaibullin R, Wilke-Olson E, et al. Epithelial-to-mesenchymal transition is associated with increased hypoxia-related angiogenesis and correlates with poor survival in glioblastoma. J Neuro-Oncol. 2011;102:249–57. https://doi.org/10.1007/s11060-011-0802-9.
40. Guryanova OA, Wu Q, Cheng L, Lathia JD, Huang Z, Yang J, et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell. 2011; 19:498–511. https://doi.org/10.1016/j.ccr.2011.03.004.

41. Wick W, Weller M, van den Bent M, Sanon M, Weiler M, von Deimling A, et al. MGMT testing—the challenges for biomarker-based glioma treatment. Nat Rev Neurol. 2014;10:372–85. https://doi.org/10.1038/nrneurol.2014.100.

42. Crespo I, Vital AL, Gonzalez-Tablas M, Patino Mdel C, Otero A, Lopes MC, et al. Molecular and genomic alterations in glioblastoma multiforme. Am J Pathol. 2015;185:1820–33. https://doi.org/10.1016/j.ajpath.2015.02.023.

43. Hegi ME, Diserens A-C, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003. https://doi.org/10.1056/NEJMoa043331.

44. Han TJ, Cho BJ, Choi EJ, Kim DH, Song SH, Paek SH, et al. Inhibition of STAT3 enhances the radiosensitizing effect of temozolomide in glioblastoma cells in vitro and in vivo. J Neuro-Oncol. 2016;130:89–98. https://doi.org/10.1007/s11060-016-2231-9.

45. Xue H, Yuan G, Guo X, Liu Q, Zhang J, Gao X, et al. A novel tumor-promoting mechanism of IL6 and the therapeutic efficacy of tocilizumab: hypoxia-induced IL6 is a potent autophagy initiator in glioblastoma via the p-STAT3-MIR155-3p-CREBRF pathway. Autophagy. 2016;12:1129–52. https://doi.org/10.1080/15548627.2016.1178446.

46. Haftchenary S, Luchman HA, Jouk AO, Veloso AJ, Page BDG, Cheng XR, et al. Potent targeting of the STAT3 protein in brain cancer stem cells: a promising route for treating glioblastoma. ACS Med Chem Lett. 2013;4:1102–7. https://doi.org/10.1021/ml4003138.

47. Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15:234–48. https://doi.org/10.1038/nrclinonc.2018.8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.